OnKure Therapeutics, Inc. (OKUR)
| Market Cap | 32.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.06M |
| Shares Out | 13.51M |
| EPS (ttm) | -8.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,888 |
| Open | 2.420 |
| Previous Close | 2.400 |
| Day's Range | 2.382 - 2.440 |
| 52-Week Range | 1.700 - 19.999 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 32.25 (+1,249.37%) |
| Earnings Date | Aug 14, 2025 |
About OKUR
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado. [Read more]
Analyst Forecast
According to 4 analysts, the average rating for OKUR stock is "Strong Buy." The 12-month stock price forecast is $32.25, which is an increase of 1,249.37% from the latest price.
News
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024
OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences
BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncol...
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported
OnKure Announces New Date for Upcoming Investor Call
Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, December 10th, at 7 a.m. CT Investor call to review preliminary data from the PIKture-01 trial is now pla...
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond
Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-2...